News headlines about AbbVie (NYSE:ABBV) have trended positive on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AbbVie earned a media sentiment score of 3.00 on their scale. InfoTrie also assigned media headlines about the company an news buzz score of 10 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock’s share price in the immediate future.
Here are some of the news articles that may have impacted AbbVie’s score:
- AbbVie Stock Rises 6% – Yahoo Finance (finance.yahoo.com)
- $8.35 Billion in Sales Expected for AbbVie Inc (NYSE:ABBV) This Quarter (americanbankingnews.com)
- AbbVie (ABBV) Gains But Lags Market: What You Should Know – Yahoo Finance (finance.yahoo.com)
- AbbVie, Roche leukemia drug successful in Phase III confirmatory study – MedCity News (medcitynews.com)
- AbbVie won’t enforce patents for COVID-19 drug candidate Kaletra – – pharmaphorum (pharmaphorum.com)
ABBV has been the subject of several research reports. Cowen lifted their price target on shares of AbbVie from $98.00 to $105.00 and gave the company an “outperform” rating in a report on Tuesday, February 18th. Royal Bank of Canada reiterated a “hold” rating and set a $86.00 price objective on shares of AbbVie in a research note on Thursday, January 23rd. Bank of America lowered shares of AbbVie from a “buy” rating to a “neutral” rating in a report on Friday, January 3rd. Societe Generale cut shares of AbbVie from a “buy” rating to a “hold” rating in a research report on Monday. Finally, Barclays started coverage on shares of AbbVie in a report on Thursday, February 27th. They set an “equal weight” rating and a $97.00 price target for the company. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $91.83.
AbbVie (NYSE:ABBV) last posted its earnings results on Friday, February 7th. The company reported $2.21 EPS for the quarter, topping analysts’ consensus estimates of $2.19 by $0.02. AbbVie had a net margin of 23.69% and a negative return on equity of 162.54%. The firm had revenue of $8.70 billion during the quarter, compared to analysts’ expectations of $8.68 billion. During the same quarter in the prior year, the business earned $1.90 earnings per share. The business’s revenue for the quarter was up 4.8% compared to the same quarter last year. Research analysts anticipate that AbbVie will post 10.52 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $1.18 per share. This represents a $4.72 dividend on an annualized basis and a yield of 6.39%. The ex-dividend date of this dividend is Tuesday, April 14th. AbbVie’s dividend payout ratio is 52.80%.
In other news, VP Brian L. Durkin bought 2,200 shares of the stock in a transaction on Wednesday, March 18th. The stock was acquired at an average price of $68.18 per share, with a total value of $149,996.00. Following the acquisition, the vice president now directly owns 15,294 shares in the company, valued at $1,042,744.92. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Brian L. Durkin bought 3,750 shares of the stock in a transaction on Friday, March 20th. The stock was purchased at an average cost of $68.82 per share, with a total value of $258,075.00. Following the acquisition, the vice president now owns 15,294 shares in the company, valued at $1,052,533.08. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 8,825 shares of company stock valued at $671,852. 0.08% of the stock is owned by corporate insiders.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
Read More: Cost of Capital Explained
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.